Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends by Region (2024)
5.2 Pharmaceutical Volume – Production & Usage (2024)
5.3 Healthcare Spending on NASH Treatment (2024)
5.4 Diagnostic and Screening Trends
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Drug
7.1 Chapter Overview
7.2 Vitamin E and Pioglitazone
7.2.1 Vitamin E and Pioglitazone Market Trends Analysis (2021-2032)
7.2.2 Vitamin E and Pioglitazone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Obeticholic Acid (OCA)
7.3.1 Obeticholic Acid (OCA) Market Trends Analysis (2021-2032)
7.3.2 Obeticholic Acid (OCA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Resmetirom
7.4.1 Resmetirom Market Trends Analysis (2021-2032)
7.4.2 Resmetirom Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Lanifibranor
7.5.1 Lanifibranor Market Trends Analysis (2021-2032)
7.5.2 Lanifibranor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Semaglutide
7.6.1 Semaglutide Market Trends Analysis (2021-2032)
7.6.2 Semaglutide Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Cenicriviroc
7.7.1 Cenicriviroc Market Trends Analysis (2021-2032)
7.7.2 Cenicriviroc Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Aramchol
7.8.1 Aramchol Market Trends Analysis (2021-2032)
7.8.2 Aramchol Market Size Estimates and Forecasts to 2032 (USD Billion)
7.9 Other Drugs
7.9.1 Other Drugs Market Trends Analysis (2021-2032)
7.9.2 Other Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Disease Stage
8.1 Chapter Overview
8.2 NASH Stage F0
8.2.1 NASH Stage F0 Market Trend Analysis (2021-2032)
8.2.2 NASH Stage F0 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 NASH Stage F1
8.3.1 NASH Stage F1 Market Trends Analysis (2021-2032)
8.3.2 NASH Stage F1 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 NASH Stage F2
8.4.1 NASH Stage F2 Market Trends Analysis (2021-2032)
8.4.2 NASH Stage F2 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 NASH Stage F3
8.5.1 NASH Stage F3 Market Trends Analysis (2021-2032)
8.5.2 NASH Stage F3 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 NASH Stage F4
8.6.1 NASH Stage F4 Market Trends Analysis (2021-2032)
8.6.2 NASH Stage F4 Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Retail and Specialty Pharmacies
9.2.1 Retail and Specialty Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Retail and Specialty Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospital Pharmacies
9.3.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Other Pharmacies
9.4.1 Other Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Other Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.4 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.5 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.6.2 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.6.3 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.7.2 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.7.3 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.8.2 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.8.3 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.4 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.5 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.6.2 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.6.3 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.7.2 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.7.3 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.8.2 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.8.3 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.9.2 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.9.3 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.10.2 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.10.3 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.11.2 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.11.3 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.12.2 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.12.3 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.4 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.5 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.6.2 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.6.3 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.7.2 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.7.3 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.8.2 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.8.3 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.9.2 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.9.3 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.10.2 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.10.3 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.11.2 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.11.3 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.6.2 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.6.3 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Saudi Arabia
10.5.8.1 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.8.2 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.8.3 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 Qatar
10.5.9.1 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.9.2 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.9.3 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 South Africa
10.5.10.1 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.10.2 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.10.3 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.11 Rest of Middle East & Africa
10.5.11.1 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.11.2 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.11.3 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.4 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.5 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.6.2 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.6.3 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.7.2 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.7.3 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Madrigal Pharmaceuticals Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Intercept Pharmaceuticals, Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Galmed Pharmaceuticals Ltd
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Inventiva
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Galectin Therapeutics Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Novo Nordisk A/S
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 NGM Biopharmaceuticals, Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 AbbVie Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 The Bristol-Myers Squibb Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Gilead Sciences, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
